Rethinking Brand Recall in Pharma

In pharma, brand and communications are treated as the same thing. They aren't.

A brand is a meaning system - the full set of associations, expectations, and emotional weight that a name or symbol carries in someone's mind. Branding is the infrastructure that makes those associations retrievable: the colors, sounds, and consistent cues that convert meaning into recall when it matters. Communications is the encoding mechanism - how those associations get built over time.

In Rx communications, things get complicated. What most categories would call the moment of purchase is, in pharma, a moment of treatment choice , and increasingly that's a shared decision between clinician and patient. For the patient, it arrives loaded with emotion - hope, yes, but also the reminder that something is wrong. When clinicians say they are happy to have another tool in the armamentarium, they have told you exactly how they see brands.

This exposes something true about pharma branding: we are not building one memory system. We are building two different ones for two different audiences.

For HCPs, the product needs a clear retrieval cue. When they see a patient with a particular need, they need to know where in the toolbox to look. For patients, the brand is an identity signal - something that makes the clinical feel meaningful, so that when the clinician goes to write the script, the patient is already there with them.

What makes pharma different from almost every other category is that neither audience can complete the purchase alone. The HCP making a treatment decision has to account for what the patient has already seen, what they believe, what they're willing to accept. The patient who has identified with a product still needs the clinician to get there with them, and may not have the vocabulary to make that happen. The creative has to serve the handoff, not just the individual audience. Most pharma organizations understand shared decision making as a clinical concept. Fewer have asked what it means for how they train their field force, or whether a rep can speak to what the patient has already seen.

This is why “matching luggage,” the instinct to make HCP and patient work look and sound the same, can feel dissonant.

When we try to unify the story around a single mental model, we flatten the two very different kinds of recall we're actually trying to build. The better brief doesn't ask how to make the HCP and patient work look alike. It asks how HCP creative can build a retrieval cue with the patient's mindset already in it, and how patient creative can build an identity signal that empowers someone to walk into an appointment and ask for what they want.

Dermatology makes this visible in a way other categories don't. Rx topicals now sit on shelves next to high-end aesthetic products that lead with their science and take their packaging seriously. The logo matters. The tube matters. Someone will open your medicine chest when they come over for dinner, and what they see says something.

Women’s health is showing the same shift from another angle, especially in the blurry territory where HCP recommendation and consumer discovery overlap. A practitioner might recommend Bonafide in the same breath as an Rx. A patient might arrive having already found it on her own. And the brands that are winning in that space are the ones that understood identity signaling from the start.

A brand is what distinguishes you. But in pharma, the better question is not simply what makes the brand different. It is what kind of recall the brand needs to create, in whose mind, and at what moment in the decision. That should be the first question in the brief, not a correction made during executional review.